- Theracryf
- 12 May 2025 13:01:58
Source: Sharecast
The AIM-traded firm said that under the agreement, Pharmaron would carry out the remaining preclinical work required to support an application for clinical trial authorisation, including manufacturing scale-up, formulation, clinical supply, and regulatory-compliant toxicology studies.
It said the work, funded in part by proceeds from TheraCryf’s recent fundraise, represented the final stage of preclinical development before human trials.
Activities were set to begin imminently, with full completion of the necessary studies anticipated in the second half of 2026.
“Following our £4.25m gross fundraise in the first quarter of this year, we are now moving at pace with our acquired and potentially most valuable programme, Ox-1,” said chief executive officer Dr Huw Jones.
“Blocking the Ox-1 receptor has the potential to alleviate a number of addictive and impulsive conditions.
“We look forward to proceeding towards clinical trials in man as quickly and efficiently as possible with Pharmaron as our development partner.”
At 1049 BST, shares in TheraCryf were up 13.11% at 0.27p.
Reporting by Josh White for Sharecast.com.